Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Spero Therapeutics(SPRO.US) Q4 2023 Earnings Conference
The following is a summary of the Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript:
以下是Spero Therapeutics, Inc.（SPRO）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Spero Therapeutics reported having cash and cash equivalents worth $76.3 million as of December 31, 2023.
Spero received a total of $95 million in milestones from GSK, to be paid in installments during 2024 and 2025.
Total revenue for Q4 2023 was $73.5 million, up from $47.4 million in Q4 2022. Total revenue for 2023 was $103.8 million, nearly double the $53.5 million revenue in 2022, mostly due to collaborations with GSK and Pfizer.
R&D expenses for 2023 totaled $51.4 million, slightly up from $47.6 million in 2022. G&A expenses were reduced to $25.6 million from $36.5 million in the previous year.
The net income reported for Q4 2023 was $51.2 million, with a full-year net income of $22.8 million; this was reflected in diluted earnings per share of $0.96 and $0.43 respectively.
Spero Therapeutics报告称，截至2023年12月31日，现金及现金等价物价值7,630万美元。
Spero从葛兰素史克获得了总额为9500万美元的里程碑资金，将在2024年和2025年分期支付。
2023年第四季度的总收入为7,350万美元，高于2022年第四季度的4,740万美元。2023年的总收入为1.038亿美元，几乎是2022年的5,350万美元收入的两倍，这主要归因于与葛兰素史克和辉瑞的合作。
2023年的研发费用总额为5140万美元，略高于2022年的4,760万美元。并购费用从去年的3,650万美元减少到2560万美元。
2023年第四季度报告的净收益为5,120万美元，全年净收入为2,280万美元；这反映在摊薄后的每股收益分别为0.96美元和0.43美元。
Business Progress:
业务进展：
SPR720 designed for NTMPD progressed to a Phase 2a proof-of-concept clinical trial, with data due by the second half of the year. Two Phase 1 studies involving the intrapulmonary pharmacokinetics of SPR719 are also underway.
Phase 3 trials of tebipenem HBr for treating urinary tract infections have started in January, with a target enrollment of 2,648 patients, to be completed by 2025.
FDA clearance received for SPR206, an antibiotic for multi-drug resistant gram-negative infections.
SPR720 has also received several recognitions including orphan drug, QIDP, and Fast Track designations.
Partnerships with GSK, Pfizer, and Everest, and associations with government agencies, have secured funding for business operations.
A strong balance sheet and financial flexibility position Spero to execute its plans effectively.
专为 NTMPD 设计的 SPR720 已进入 2a 期概念验证临床试验，数据将于下半年公布。两项涉及 SPR719 肺内药代动力学的 1 期研究也在进行中。
用于治疗尿路感染的替比培南HBr的3期试验已于1月开始，目标招收2648名患者，到2025年完成。
用于耐多药革兰阴性感染的抗生素 SPR206 已获美国食品药品管理局批准。
SPR720 还获得了多项认可，包括孤儿药、QIDP 和 Fast Track 称号。
与葛兰素史克、辉瑞和珠穆朗玛峰的合作伙伴关系，以及与政府机构的协会，为企业运营提供了资金。
强劲的资产负债表和财务灵活性使Spero能够有效地执行其计划。
More details: Spero Therapeutics IR
更多详情： Spero 疗法 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。